Transdel Pharmaceuticals to Present at 2008 BIO International Convention

Wednesday, June 18, 2008 General News J E 4
LA JOLLA, Calif., June 17 TransdelPharmaceuticals, Inc. (OTC Bulletin Board: TDLP), a specialty pharmaceuticalcompany focused on the development and commercialization of non-invasivetopically administered medications, today announced that Dr. Juliet Singh,President and Chief Executive Officer, will present at the 2008 BIOInternational Convention to be held June 17 - 20, 2008 at the San DiegoConvention Center in San Diego, CA

Dr. Singh's 15-minute corporate overview will take place on Friday,June 20, 2008 at 10:15 a.m. (PDT) in room 5B of the Drug Delivery track.For more information on this event please visit:

About Transdel Pharmaceuticals, Inc.

Transdel Pharmaceuticals, Inc. (OTCBB: TDLP) is a specialty pharmaceuticalcompany focused on the development and commercialization of non-invasivetopically delivered medications. The Company's lead topical drug,Ketotransdel(TM), utilizes the Company's innovative patented proprietaryTransdel(TM) cream formulation technology to facilitate the passage ofketoprofen, an NSAID, through the skin barrier to reach targeted underlyingtissue where the drug exerts its prolonged localized anti-inflammatory andanalgesic effect. The Company is also investigating other drug candidates andtreatments for transdermal delivery using the patented Transdel(TM) platformtechnology for products in pain management and other therapeutic areas.

Safe Harbor Statement

The statements which are not historical facts contained in this pressrelease are forward-looking statements that involve certain risks anduncertainties including but not limited to risks associated with theuncertainty of future financial results, additional financing requirements,development of new products, government approval processes, the impact ofcompetitive products or pricing, technological changes, the effect of economicconditions and other uncertainties detailed in the Company's filings with theSecurities and Exchange Commission.

SOURCE Transdel Pharmaceuticals, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Neurocrine Biosciences Completes 'Petal Study' Tre...
Shengtai Pharmaceutical, Inc. Announces Progress o...